Novartis (VTX:NOVN) PT Set at CHF 80 by Barclays

Barclays set a CHF 80 price target on Novartis (VTX:NOVN) in a research report released on Thursday, July 19th. The firm currently has a neutral rating on the stock.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group set a CHF 98 target price on shares of Novartis and gave the stock a buy rating in a report on Friday, April 13th. HSBC set a CHF 84 target price on shares of Novartis and gave the stock a buy rating in a report on Wednesday, April 11th. Cfra set a CHF 91 target price on shares of Novartis and gave the stock a buy rating in a report on Tuesday, March 27th. Baader Bank set a CHF 95 target price on shares of Novartis and gave the stock a buy rating in a report on Tuesday, March 27th. Finally, Oddo Bhf set a CHF 88 price target on shares of Novartis and gave the stock a buy rating in a research report on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. Novartis currently has an average rating of Hold and an average target price of CHF 88.65.

Shares of Novartis traded up CHF 0.34, hitting CHF 78.38, during trading hours on Thursday, Marketbeat.com reports. 11,210,000 shares of the company’s stock traded hands, compared to its average volume of 5,980,000. Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: Diversification For Individual Investors

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply